Nordic Nanovector ASA: Annual General Meeting Held
OSLO, Norway, April 25, 2019 /PRNewswire/ -- The Annual General Meeting of Nordic Nanovector ASA (the "Company") (OSE: NANO) was held today on 25 April 2019 in Oslo, Norway.
All proposals were resolved by the Annual General Meeting as presented in the notice convening the general meeting distributed on 4 April 2019.
The complete minutes of the Annual General Meeting are attached to this release, and are available on www.nordicnanovector.com.
For further information, please contact:
Malene Brondberg, VP Investor Relations and Corporate Communications
Cell: +44-7561-431-762
Email: [email protected]
About Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.
Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37 -targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.
This information is subject to a duty of disclosure pursuant to Section 5-12 of the Norwegian Securities Trading Act.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
https://mb.cision.com/Public/9819/2797177/8af28576d92e572c.pdf |
Nordic Nanovector Minutes Annual General Meeting |
SOURCE Nordic Nanovector
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article